Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial
Raiko Blondonnet,Laure-Anne Simand,Perine Vidal,Lucile Borao,Nathalie Bourguignon,Dominique Morand,Lise Bernard,Laurence Roszyk,Jules Audard,Thomas Godet,Antoine Monsel,Marc Garnier,Christophe Quesnel,Jean-Etienne Bazin,Vincent Sapin,Julie A Bastarache,Lorraine B Ware,Christopher G Hughes,Pratik P Pandharipande,E Wesley Ely,Emmanuel Futier,Bruno Pereira,Jean-Michel Constantin,Matthieu Jabaudon,On Behalf Of The Sesar Collaborative Group
DOI: https://doi.org/10.3390/jcm11102796
2022-05-16
Abstract:Preclinical studies have shown that volatile anesthetics may have beneficial effects on injured lungs, and pilot clinical data support improved arterial oxygenation, attenuated inflammation, and decreased lung epithelial injury in patients with acute respiratory distress syndrome (ARDS) receiving inhaled sevoflurane compared to intravenous midazolam. Whether sevoflurane is effective in improving clinical outcomes among patients with ARDS is unknown, and the benefits and risks of inhaled sedation in ARDS require further evaluation. Here, we describe the SESAR (Sevoflurane for Sedation in ARDS) trial designed to address this question. SESAR is a two-arm, investigator-initiated, multicenter, prospective, randomized, stratified, parallel-group clinical trial with blinded outcome assessment designed to test the efficacy of sedation with sevoflurane compared to intravenous propofol in patients with moderate to severe ARDS. The primary outcome is the number of days alive and off the ventilator at 28 days, considering death as a competing event, and the key secondary outcome is 90 day survival. The planned enrollment is 700 adult participants at 37 French academic and non-academic centers. Safety and long-term outcomes will be evaluated, and biomarker measurements will help better understand mechanisms of action. The trial is funded by the French Ministry of Health, the European Society of Anaesthesiology, and Sedana Medical.